Jiangsu Kanion Pharmaceutical Navigates Challenges with Strategic Acquisitions and Innovation
Jiangsu Kanion Pharmaceutical Co Ltd navigated a challenging year with a 20% revenue decline, but showed resilience with a surge in stock price and strategic initiatives in innovation and acquisitions.
- Jiangsu Kanion Pharmaceutical Co Ltd
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read